HCV Protease Inhibitors

Glecaprevir

Products Glecaprevir was approved in the United States, many countries, and the EU in 2017 as a fixed-dose combination with pibrentasvir in film-coated tablet form (Maviret). Structure and properties Glecaprevir (C38H46F4N6O9S, Mr = 838.9 g/mol) exists as a white crystalline powder. Effects Glecaprevir has antiviral properties. The effects are due to inhibition of the viral … Glecaprevir

Grazoprevir

Products Grazoprevir was approved in many countries in 2015 as film-coated tablets in fixed combination with the NS5A inhibitor elbasvir (Zepatier). Structure and properties Grazoprevir (C38H52N6O10S, Mr = 784.9 g/mol) Effects Grazoprevir has antiviral properties. The effects are due to inhibition of HCV protease, which converts the viral polyprotein into the active proteins. The protease … Grazoprevir